Literature DB >> 27977122

Comparative Analysis of the Neurochemical Profile and MAO Inhibition Properties of N-(Furan-2-ylmethyl)-N-methylprop-2-yn-1-amine.

Philippe De Deurwaerdère1, Claudia Binda2, Rémi Corne1, Cosima Leone3, Aurora Valeri4, Massimo Valoti3, Rona R Ramsay5, Yagamare Fall6, José Marco-Contelles7.   

Abstract

The regulation of brain monoamine levels is paramount for cognitive functions, and the monoamine oxidase (MAO A and B) enzymes play a central role in these processes. The aim of this study was to evaluate whether the procognitive properties exerted by propargylamine N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA) are related to changes in monoamine content via MAO inhibition. In vivo microdialysis and ex vivo amine metabolite measurement demonstrated region-specific alterations in monoamine metabolism that differ from both of the classic MAO A and MAO B inhibitors, clorgyline and l-deprenyl, respectively. Although all the inhibitors (1 and 4 mg/kg) increased cortical serotonin tissue content, only F2MPA increased the levels of cortical noradrenaline. In the striatum, clorgyline (1 mg/kg), but not F2MPA (1 mg/kg), reduced extracellular levels of dopamine metabolites at rest or stimulated by the intrastriatal application of the MAO substrate 3-methoxytyramine. In vitro, F2MPA exhibited a low affinity toward MAO B and MAO A. Nonetheless, it modified the B form of MAO, forming a flavin adduct structurally similar to that with deprenyl. F2MPA was rapidly metabolized in the presence of rat but not human microsomes, producing a hydroxylated derivative. In conclusion, the effect of F2MPA on cognition may arise from monoaminergic changes in the cortex, but the role of MAO in this process is likely to be negligible, consistent with the poor affinity of F2MPA for MAO.

Entities:  

Keywords:  Alzheimer’s disease; Propargylamines; crystallography; enzymology; monoamine neurochemistry; neuroprotection

Mesh:

Substances:

Year:  2016        PMID: 27977122     DOI: 10.1021/acschemneuro.6b00377

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  7 in total

1.  Design, Synthesis, and Biological Evaluation of Novel MAO-A Inhibitors Targeting Lung Cancer.

Authors:  Sanaa Bardaweel; Reem Aljanabi; Dima Sabbah; Kamal Sweidan
Journal:  Molecules       Date:  2022-04-30       Impact factor: 4.927

Review 2.  Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs.

Authors:  Rona R Ramsay; Keith F Tipton
Journal:  Molecules       Date:  2017-07-15       Impact factor: 4.411

3.  Parameters for Irreversible Inactivation of Monoamine Oxidase.

Authors:  Rona R Ramsay; Livia Basile; Antonin Maniquet; Stefanie Hagenow; Matteo Pappalardo; Maria Chiara Saija; Sharon D Bryant; Alen Albreht; Salvatore Guccione
Journal:  Molecules       Date:  2020-12-13       Impact factor: 4.411

4.  A perspective on multi-target drug discovery and design for complex diseases.

Authors:  Rona R Ramsay; Marija R Popovic-Nikolic; Katarina Nikolic; Elisa Uliassi; Maria Laura Bolognesi
Journal:  Clin Transl Med       Date:  2018-01-17

5.  Chronic Administration of Fipronil Heterogeneously Alters the Neurochemistry of Monoaminergic Systems in the Rat Brain.

Authors:  Rahul Bharatiya; Abdeslam Chagraoui; Salomé De Deurwaerdere; Antonio Argiolas; Maria Rosaria Melis; Fabrizio Sanna; Philippe De Deurwaerdere
Journal:  Int J Mol Sci       Date:  2020-08-09       Impact factor: 5.923

6.  β-Naphtoflavone and Ethanol Induce Cytochrome P450 and Protect towards MPP⁺ Toxicity in Human Neuroblastoma SH-SY5Y Cells.

Authors:  Jesus Fernandez-Abascal; Mariantonia Ripullone; Aurora Valeri; Cosima Leone; Massimo Valoti
Journal:  Int J Mol Sci       Date:  2018-10-28       Impact factor: 5.923

7.  Path Integral Calculation of the Hydrogen/Deuterium Kinetic Isotope Effect in Monoamine Oxidase A-Catalyzed Decomposition of Benzylamine.

Authors:  Mateusz Z Brela; Alja Prah; Marek Boczar; Jernej Stare; Janez Mavri
Journal:  Molecules       Date:  2019-11-28       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.